Spero Therapeutics, Inc.
SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, includingā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.52
Price+2.65%
$0.07
1Y
Price
Market Cap
$141.679m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-242.2%
EBITDA Margin-242.2%
Net Profit Margin+571.6%
Free Cash Flow Margin-242.2%
EBITDA Margin-242.2%
Net Profit Margin+571.6%
Free Cash Flow MarginRevenue
$35.768m
-25.4%
1y CAGR+11.5%
3y CAGR+379.2%
5y CAGREarnings
-$43.836m
+36.1%
1y CAGR-71.8%
3y CAGR-41.8%
5y CAGREPS
-$0.80
+37.0%
1y CAGR-74.5%
3y CAGR-41.4%
5y CAGRBook Value
$26.494m
$54.170m
Assets$27.676m
Liabilities$3.351m
DebtDebt to Assets
6.2%
-0.1x
Debt to EBITDAFree Cash Flow
-$27.674m
-18.0%
1y CAGR-105.3%
3y CAGR-79.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company